Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid)

靶向CD22嵌合抗原受体T细胞疗法

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD22 CAR T cell therapy (Wuhan Bio-Raid)
Drug Alias NameAnti-CD22 chimeric antigen receptor T-cell therapies - Wuhan Bio Raid Biotechnology
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionCD22 modulatorsImmunologic cytotoxicityT lymphocyte replacements
TargetsCD22
Therapy Area/IndicationsMultiple MyelomaLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuhan BioRaid Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan BioRaid Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A